Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ddg.15908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aseptic Abscess Associated with Ankylosing Spondylitis-Cause or Effect of Therapy? Case Report.
Eur J Rheumatol
July 2025
Department of Pathomorphology, Jagiellonian University Medical College, Kraków, Poland.
Neutrophil dermatitis is a group of diseases characterized by the leakage of neutrophils in the skin and subcutaneous tissue with a non-infectious, autoinflammatory etiology. These include the aseptic abscess syndrome (AA). Diagnosis is based on histopathological examination and the exclusion of infectious, allergic, and cancer causes.
View Article and Find Full Text PDFSerum LACC1 level is a predictor of response to upadacitinib treatment in patients with rheumatoid arthritis: a prospective observational cohort study.
Eur J Med Res
August 2025
Department of Rheumatology and Immunology, Hainan General Hospital (Hainan Medical University Hainan Hospital), No.19 Xiuhua Road, Xiuying District, Haikou City, 570311, Hainan Province, China.
Objective: This study investigates the predictive capacity of LACC1 regarding the response to upadacitinib (UPA) in individuals with rheumatoid arthritis (RA).
Methods: The study involved sixty adult patients with active RA who either did not respond well to or could not tolerate methotrexate. The regimen involved UPA monotherapy at 15 mg/day, while maintaining a fixed dose of glucocorticoids was acceptable.
Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study.
RMD Open
August 2025
AbbVie Inc, North Chicago, Illinois, USA.
Objectives: This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton's tyrosine kinase inhibitor) in adults with moderately to severely active systemic lupus erythematosus (SLE). The objective was to evaluate the efficacy and safety of an additional 56 weeks of treatment.
Methods: Patients randomised to upadacitinib 30 mg one time per day (QD) or upadacitinib 30 mg/elsubrutinib 60 mg QD (upadacitinib/elsubrutinib) in the SLEek study continued their assigned treatment during the LTE.
Upadacitinib dose adjustment in moderate-to-severe atopic dermatitis: insights from a multicenter real-world study.
J Dtsch Dermatol Ges
August 2025
Dermatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Upadacitinib Coadministered with Methylprednisolone for Effective Treatment of SJS/TEN Overlap Syndrome: A Case Report.
Clin Cosmet Investig Dermatol
August 2025
Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People's Republic of China.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) overlap syndrome, characterized by extensive epidermal necrosis, represents a life-threatening severe dermatological disorder.Therapeutic agents and regimens for this condition include high-dose glucocorticoids, intravenous immunoglobulin (IVIG), plasma exchange, immunosuppressants, and TNF-α inhibitors. A study demonstrates that JAK/STAT hyperactivation-characterized by interferon signature enrichment, STAT1 phosphorylation in keratinocytes/macrophages, and subsequent GBP1/WARS1-mediated cytotoxicity-drives epidermal detachment in TEN.
View Article and Find Full Text PDF